R&D / Progress & Potential in Hungary
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Investments in research and development are on the rise in Hungary, backed up by government initiatives, but the country needs a more unified effort between the public and private sectors…
Hungary’s two largest pharma firms, Egis Pharmaceuticals and Gedeon Richter, are stepping up their biosimilars offering; providing the European market with more affordable biologic medicines and bolstering Hungary’s footprint in…
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save billions of dollars and…
AstraZeneca’s Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather than finger-pointing, is the only way forward. Discussion…
Like many of its European counterparts, Hungary is suffering from medicine shortages. Vaccines, vitamins, and orphan drugs are some of the most affected areas and oncology patients are now also…
Awareness is growing of the dangers of healthcare-associated infections (HAIs) in Europe, and conversations are beginning to taking place around how to leverage data to combat these infections and antimicrobial…
Hungarian patients currently experience longer wait times and more limited access to subsidised innovative medicines than their neighbours in Bulgaria and Slovakia.leading some organisations to urge the government to increase…
China’s roll-out of a 25-province expansion to the 4+7 pilot procurement scheme has seen pharma companies scrambling to cut prices for their drugs even further in the latest bidding war.…
Unlike many of his pharma peers, Vivek Sharma worked in operations and finance for two decades before joining the life sciences industry as head of Piramal Pharma Solutions (PPS) in…
While Taiwanese pharmaceutical and biotech players have traditionally set their sights on the US as a key market, rising medical needs in Asia are helping foster more regionally-focused strategies. …
All country managers of multinational pharma companies need to strike the balance between having a global outlook and adapting to local culture. For BoonHuey Ee, general manager of Merck Biopharma…
Unknown to some, Switzerland meanwhile remains both influential and relevant in global pharma circles not just for the obvious core activities of research, discovery and marketing, but also for its…
See our Cookie Privacy Policy Here